[ad_1]
new York, July 10, 2021 /PRNewswire/– Pomerantz LLP announced that it has acquired AcelRx Pharmaceuticals, Inc. (“AcelRx” or “Company”) (NASDAQ:ACRX) And some of its senior staff.Class action, filed at United States North District District Court California, And recorded under 21-cv-04353, representing a category composed of all individuals and entities other than the defendant who are in March 17, 2020 with February 12, 2021, Including the first and last two days (“class action period”), seek compensation for damages caused by the defendant’s violation of the federal securities laws, and pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ) “Trading Law”) and rules 10b-5 Promulgated accordingly, targeting the company and some of its senior officials.
The full story on Benzinga.com
[ad_2]
Source link
